Navigation Links
Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
Date:12/5/2012

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in Atlanta (December 8-11, 2012). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL).

Studies presented at this year's ASH meeting will report the complete Phase 2 data set from a study demonstrating that Iomab-B (monoclonal antibody BC8 labeled with Iodine 131) provides a significant survival benefit for high risk AML patients under age 50.  At the time of the abstract writing, 36% of the patients were surviving progression free for a median of 87 months.  Other data to be presented at the meeting include Phase I dose escalating trial in enabling successful engraftment and complete remissions in transplanting patients who do not have fully matched donors.   All the patients in the trial were successfully transplanted and had a complete remission with survival benefit.

The following abstracts will be presented during the 54th Annual ASH Meeting and Exposition:

Abstract #1924:  A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Saturday, December 8, 2012, 5:30 PM - 7:30 PM (Georgia World Congress Center, Hall B1-B2)

Abstract #4164:  Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Monday, December 10, 2012, 6:00 PM - 8:00 PM (Georgia World Congress Center, Hall B1-B2)

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 isotopes in association with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr. of Dennis S. Dobson Inc., 203-258-0159
Email: dsdobson@optonline.com
www.dobsonmediagroup.com

Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel:  (646) 459-4201
E-mail: actimaba@actiniumpharmaceuticals.com

Investors:
Jeff Ramson
ProActive Capital Group, LLC
Tel:  (646) 863-6341
E-mail: jramson@proactivecrg.com
www.proactivecrg.com  

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Salveo Specialty Pharmacy, Inc. Completes Additional Equity and Debt Financings and Acquisition of Mission Road Pharmacy
2. Women with Dense Breasts Welcome Additional Screening
3. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
4. Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
5. TechPrecision Receives Additional Medical Purchase Orders Exceeding $1.5 Million
6. MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares of Common Stock
7. Medical Alarm Concepts Begins Shipments To Europe - Company Ordering Additional Inventory To Keep Up With Growing Demand
8. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
9. Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 2013
10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. GeNO LLC Receives Two Additional Patents For Inhaled Nitric Oxide Drug Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a privately-held ... and developing novel compounds to treat Parkinson,s disease (PD), has ... is a Phase 1/2a randomized, controlled, multicenter study involving patients ... will enroll 50 patients over a 9-to-12-month period. The first ... 10 patients with PD. Participating sites include Denver ...
(Date:5/10/2017)... , May 10, 2017 Global Health ... Latin America , published its 2017 ranking ... ranking is based on extensive data analysis from GHI,s ... largest hospitals database for the region. The GHI database covers ... , offering more than 130 data points for each institution ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a national ... category winner, has named Daniel P. Bullington as chief technology officer. , “i2i ... and product offerings,” says Justin Neece, president. “Daniel is an excellent fit for ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... patients on peri-implantitis in Las Vegas, NV, and the importance of ... gum disease consultation and leading care for peri-implantitis, with or without a referral. ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients with symptoms of gum disease ... receive laser gum disease treatments from the doctors at Art of Dentistry, without first ... awareness of the importance of receiving qualified treatment in order to avoid systemic health ...
(Date:5/22/2017)... ... 2017 , ... Patients who avoid necessary dental and endodontic treatments because of ... NY from Advanced Endodontics of Westchester. This highly-trained team of endodontists offer three different ... sedation methods may be recommended based on the severity of the anxiety experienced by ...
(Date:5/22/2017)... ... ... Galena, Alaska, has a population of less than 500 people. But, the ... to build a nuclear plant by the TOSHIBA Corporation. , In “The Galena Nuclear ... the journey to get power to his small town, off the electrical grid. , ...
Breaking Medicine News(10 mins):